MarketCap
Facebook
X
TelegramGeschäftsbericht 2020
hinzugefügt 19.08.2023
ASLAN Pharmaceuticals Limited Gesamtes Eigenkapital 2011-2025 | ASLN
Gesamtes Eigenkapital Jährlich ASLAN Pharmaceuticals Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | -10.2 M | -603 K | 30.6 M | 35.5 M | 41.6 M | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 41.6 M | -10.2 M | 19.4 M |
Gesamtes Eigenkapital Vierteljährlich ASLAN Pharmaceuticals Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 57.3 M | - | 75.4 M | - | -10.2 M | -11.6 M | -8 M | - | -603 K | 13.2 M | 18.4 M | - | 30.6 M | 41.8 M | - | - | 35.5 M | - | - | - | 41.6 M | - | - | - | -37.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 75.4 M | -37.6 M | 18.9 M |
Gesamtes Eigenkapital anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtes Eigenkapital | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
106 M | $ 4.95 | 4.99 % | $ 822 M |  Canada |
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
156 M | $ 3.2 | -1.48 % | $ 247 M |  USA |
 |
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
4.76 M | $ 1.06 | -5.97 % | $ 293 K | USA |
 |
Catalyst Biosciences
CBIO
|
-15.8 M | $ 13.19 | -6.39 % | $ 868 M | USA |
 |
Ascendis Pharma A/S
ASND
|
884 M | $ 213.99 | -2.92 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.1 | -5.93 % | $ 7.46 B |  Australia |
 |
Celldex Therapeutics
CLDX
|
747 M | $ 27.04 | -1.73 % | $ 1.74 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
680 M | $ 87.29 | -0.8 % | $ 9.01 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
728 M | $ 24.46 | 3.56 % | $ 2.9 B | USA |
 |
CureVac N.V.
CVAC
|
688 M | $ 5.04 | -0.3 % | $ 938 M | Germany |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
BioVie
BIVI
|
19 M | $ 1.43 | -1.38 % | $ 2.11 M | USA |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
597 M | $ 10.87 | 0.63 % | $ 1.41 B | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
39.5 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
1.37 B | $ 94.19 | -0.66 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
518 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
732 M | $ 26.28 | 4.0 % | $ 1.27 B | USA |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
212 M | $ 9.64 | 0.84 % | $ 141 M | USA |
 |
Eton Pharmaceuticals
ETON
|
15.5 M | $ 15.96 | -4.43 % | $ 409 M | USA |
 |
Evogene Ltd.
EVGN
|
56.9 M | $ 1.05 | -2.78 % | $ 27.9 M |  Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.44 M | $ 0.27 | -6.29 % | $ 588 M | Israel |
|
Foghorn Therapeutics
FHTX
|
-45.5 M | $ 4.39 | -1.13 % | $ 241 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
673 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
16.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
94.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
2.33 B | $ 548.77 | -2.75 % | $ 41.6 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
19 M | $ 2.36 | 2.61 % | $ 14.8 M | USA |
 |
AstraZeneca PLC
AZN
|
15.6 B | $ 91.51 | 1.87 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
9.93 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
1.7 B | $ 8.95 | -0.56 % | $ 1.45 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
3.33 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-739 M | $ 11.28 | -2.17 % | $ 730 M | USA |
 |
Biogen
BIIB
|
16.7 B | $ 174.19 | 0.05 % | $ 25.4 B | USA |
 |
Abeona Therapeutics
ABEO
|
14.8 M | $ 5.07 | -5.5 % | $ 108 M | USA |